We’ve treated polymetastatic disease as “too much” for RT for decades.
Our new review in @IJROBP dives into the practical realities of treating widespread disease with SABR + immunomodulatory LDRT - from patient selection to workflows that scale. @MoffittNews@drdavidpalma
FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer | FDA@ great news for our patients @MayoClinic @shilpaonc @PGrivasMDPhD https://t.co/tAwfeiACRj
From #ASTRO25: Kosj Yamoah, MD (@KOSJ12), shared findings on the Decipher genomic classifier and Artera multimodal AI biomarker in predicting metastasis in localized prostate cancer. Both outperform traditional risk tools.
Key findings:
➡️ In 306 prostate cancer cases, Decipher and Artera scores showed only weak overall correlation.
➡️Each was independently linked to distinct biological pathways in metastatic patients.
➡️Together, they may offer complementary value in defining aggressive disease.
learn more: https://t.co/k2ORbirvVZ
#MoffittASTRO25
From #ASTRO25 : Justyn Nakashima, DO (@NakashimaJustyn) shares institutional outcomes of SBRT for extracranial oligometastatic renal cell carcinoma during the poster Q&A.
Results indicate that SBRT is safe and effective, delaying systemic therapy while maintaining high LC and PFS.
#MoffittASTRO25
At the #ASTRO25 plenary session, Vedang Murthy, MD, (@VedangMurthy@TataMemorial) shares clinical outcomes of adjuvant radiotherapy (RT) after radical cystectomy (RC) and chemotherapy in locally advanced muscle-invasive bladder cancer (LA-MIBC).
➡️ Adjuvant RT improved LRFS and DFS without increased severe late toxicity in patients with LA-MIBC post cystectomy and chemotherapy.
➡️ Potential benefit in OS is being explored in a planned individual patient data meta-analysis of randomized trials.
Read more: https://t.co/CjewabUihG
#MoffittASTRO25 @ASTRO_org
Strong 💪🏻 work from a stellar resident @celinachiodo presenting @MoffittNews early experience with online hypofx adaptive bladder radiation. Awesome support by @MoffittRadOnc physics in making this an option for our patients
Incredibly honored to be 1 of 12 residents in the country to receive a Recognition Meeting Abstract Award for our work on Adaptive Radiotherapy for Locally Advanced Lung Cancer. So thankful for my mentors and Moffitt Cancer Center for supporting our research. #ASTRO25
Great job @DK_18621 presenting your research on the use of ctDNA in post-TMT surveillance. Much to learn with this data. 🚨 Rising ⭐️ @MoffittRadOnc@MoffittNews
Radiation vs systemic therapy for isolated pelvic recurrence after cystectomy. @UroDocAsh moderates a debate between @AndreaNecchi@SanRaffaeleMI & Comron Hassanzadeh, MD, MPH @MDAndersonNews. Comron Hassanzadeh backs pelvic radiation for isolated recurrence, while Andrea Necchi highlights systemic therapy with EV-pembro and data from EV-302 & CheckMate-901. Both stress the importance of biomarkers, patient input & multidisciplinary care.
🎥 #WatchNow > https://t.co/HokqRPm1Zz